Elevated levels of some neuroactive progesterone metabolites, particularly isopregnanolone, in women with chronic fatigue syndrome

Psychoneuroendocrinology

Volumn 29, Issue 2, 2004, Pages 245-268

  Murphy, B E Pearson ^a,b   Abbott, F V ^a   Allison, C M ^a   Watts, C ^b   Ghadirian, A M ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Chronic fatigue syndrome; Depression; Epipregnanolone; Isopregnanolone; Pregnanedione; Pregnanolone; Pregnenolone; Progesterone

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 3BETA HYDROXY 5BETA PREGNAN 20 ONE; 3BETA,5ALPHA TETRAHYDROPROGESTERONE; 5ALPHA PREGNANE 3,20 DIONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ELTANOLONE; HORMONE PRECURSOR; ISOPREGNANOLONE; NEUROSTEROID; PREGNANEDIONE; PREGNENOLONE; PROGESTERONE; PROGESTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; FEMALE; FOLLICULAR PHASE; HAMILTON SCALE; HORMONE BLOOD LEVEL; HUMAN; MENSTRUAL CYCLE; METABOLITE; MULTIVARIATE ANALYSIS OF COVARIANCE; OVARY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROGESTERONE METABOLISM;

EID: 0242321131     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(03)00026-X     Document Type: Article

References (55)

1. Atkinson R.M., Davis B., Pratt M.A., Sharpe H.M., Tomich E.G. Action of some steroids on the central nervous system of the mouse. J. Med. Chem. 8:1965;426-432.
2. Bäckstrom T., Andersson A., Baird D.T., Selstam G. The human corpus luteum secretes 5 alpha-pregnane-3,20-dione. Acta Endocrinol. (Copenh.). 111:1986;116-121.
3. Bičikova M., Lapčik O., Hampl R., Starka L., Knuppen R., Haupt O., et al. A novel radioimmunoassay of allopregnanolone. Steroids. 60:1995;210-213.
4. Bičikova M., Dibbelt L., Hill M., Hampl R., Stárka L. Allopregnanolone in women with premenstrual syndrome. Horm. Metab. Res. 30:1998;227-230.
5. Chalder T., Berelowitz G., Pawlikowska T., Watts L., Wessely S., Wright D., et al. Development of a fatigue scale. J. Psychosom. Res. 37:1993;147-153.
6. Cleare A.J., Heap E., Malhi G.S., Wessely S., O'Keane V., Miell J. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet. 353:1999;455-458.
7. DeGroot, L.J., (Ed.), 2001. Endocrinology, third ed., vol. 2. WB Saunders Co., Philadelphia, PA, pp 2594.
8. Derogatis L.R., Rickels K., Rock A.F. The SCL-90 and the MMPI: a step in the validation of a new self-report scale. Br. J. Psychiatry. 128:1977;280-289.
9. Dhar V., Stark R., Kraulis I., Murphy B.E. Contrasting effects of 5 alpha- and 5 beta-pregnane-3,20-dione on the motor activity of ovariectomized rats. J. Steroid Biochem. 26:1987;577-580.
10. Diagnostic and Statistical Manual of Mental Disorders (DSM IV), 1994. American Psychiatric Association, Washington, DC.
11. Epperson C.N., Haga K., Mason G.F., Sellers E., Gueorguieva R., Zhang W., Weiss E., Rothman D.L., Krystal J.H. Arch. Gen. Psychiatry. 59:2002;851-858.
12. Freeman E.W., Purdy R.H., Coutifaris C., Rickels K., Paul S.M. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology. 58:1993;478-484.
13. Fukuda T., Strauss S.E., Hickie I., Sharpe M.C., Dobbins J.G., Komaroff A.L., et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann. Intern. Med. 121:1994;953-959.
14. Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 32:1959;50-55.
15. Heim C., Heim C., Ehlert U., Hellhammer D.H. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology. 25:2000;1-35.
16. Jung-Testas I., Do T., Koenig H., Desarnaud F., Shazand K., Schumacher M., et al. Progesterone as a neurosteroid: synthesis and actions in rat glial cells. J. Steroid Biochem. Mol. Biol. 69:1999;97-107.
17. Laposata M. The New England Journal of Medicine SI Unit Conversion Guide. 1992;NEJM Books, Boston, MA. p. 43.
18. van der Linden G., Chalder T., Hickie I., Koschera A., Sham P., Wessely S. Fatigue and psychiatric disorder: different or the same? Psychol. Med. 29:1999;863-868.
19. Maitra R., Reynolds J.N. Modulation of GABA(A) receptor function by neuroactive steroids: evidence for heterogeneity of steroid sensitivity of recombinant GABA(A) receptor isoforms. Can. J. Physiol. Pharmacol. 76:1998;909-920.
20. McKenzie R., O'Fallon A., Dale J., Demitrack M., Sharma G., Deloria M., et al. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA. 280:1998;1061-1066.
21. Meczekalski B., Tonetti A., Monteleone P., Bernardi F., Luisi S., Stomati M., et al. Hypothalamic amenorrhea with normal body weight: ACTH, allopregnanolone and cortisol responses to corticotropin-releasing hormone test. Eur. J. Endocrinol. 142:2000;280-285.
22. Milewich L., Gomez-Sanchez C., Crowley G., Porter J.C., Madden J.D., MacDonald P.C. Progesterone and 5α-pregnane-3,20-dione in peripheral blood of normal young women. Daily measurements throughout the menstrual cycle. J. Clin. Endocrinol. Metab. 45:1977;617-622.
23. Monteleone P., Luisi S., Tonetti A., Bernardi F., Genazzani A.D., Luisi M., et al. Allopregnanolone concentrations and premenstrual syndrome. Eur. J. Endocrinol. 142:2000;269-273.
24. Moss-Morris R., Petrie K.J. Discriminating between chronic fatigue syndrome and depression: a cognitive analysis. Psychol. Med. 31:2001;469-479.
25. Murphy B.E.P. Steroids and depression. J. Steroid Biochem. Mol. Biol. 38:1991;537-559.
26. Murphy B.E.P. Urinary free cortisol levels: what they measure. The Endocrinologist. 12:2002;143-154.
27. Murphy B.E.P., Allison C.M. Determination of progesterone and some of its ring A-reduced metabolites in human serum. J. Steroid Biochem. Mol. Biol. 74:2000;137-142.
28. Murphy, B.E.P., Ghadirian, A.-M., Allison, C., 2000. Neuroactive steroids in chronic fatigue syndrome (CFS), Program Annual Meeting Am Psychiatric Association, Chicago. Syllabus and Proceedings Summary, p. 40 (Abstract).
29. Murphy, B.E.P., Steinberg, S.I., Allison, Ghadirian A.-M., 2001a. Neuroactive A ring-reduced steroids (NARS) and behaviour, ISPNE XXXII Annual Congress, Quebec City, Canada (Abstract).
30. Murphy B.E.P., Steinberg S.I., Hu F.Y., Allison C.M. Neuroactive ring A-reduced metablites of progesterone in human plasma during pregnancy: elevated levels of 5α-dihydroprogesterone in depressed patients during the latter half of pregnancy. J. Clin. Endocrinol. Metab. 86:2001b;5981-5987.
31. Chronic Fatigue Syndrome Information for Physicians. 1996;National Institutes of Health, Public Health Service, US Department of Health and Human Services.
32. Nesse R.M. Is depression an adaptation? Arch. Gen. Psychiatry. 57:2000;14-20.
33. Paul S.M., Purdy R.H. Neuroactive steroids. FASEB J. 6:1992;2311-2322.
34. Purdy R.H., Moore P.H. Jr., Rao P.N., Hagino N., Yamaguchi T., Schmidt P., et al. Radioimmunoassay of 3α-hydroxy-5α-pregnan-20-one in rat and human plasma. Steroids. 55:1990;290-294.
35. Rall T.W. Hypnotics and sedatives; ethanol. Gilman A.G., Rall T.W., Nies A.S., Taylor P. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 1990;345-382 Pergamon Press, New York.
36. Rehm L.P., O'Hara M.W. Item characteristics of the Hamilton rating scale for depression. J. Psychiatr. Res. 19:1985;31-41.
37. Richman J.A., Jason L.A., Taylor R.R., Jahn S.C. Feminist perspectives on the social construction of chronic fatigue syndrome. Health Care Women Int. 21:2000;173-185.
38. Romeo E., Ströhle A., Spalletta G., Di Michele F., Hermann B., Holsboer F., et al. Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry. 1555:1998;910-913.
39. Schmitz N., Hartkamp N., Franke G.H. Assessing clinically significant change: application to the SCL-90-R. Psychol. Rep. 86:2000;263-274.
40. Steven I.D., McGrath B., Qureshi F., Wong C., Chern I., Pearn-Rowe B. General practitioners' beliefs, attitudes and reported actions towards chronic fatigue syndrome. Aust. Fam. Physician. 29:2000;80-85.
41. Ströhle A., Pasini A., Romeo E., Hermann B., Spalletta G., Holsboer F., et al. Fluoxetine decreases concentrations of 3α,5α- tetrahydrodeoxycorticosterone (THDOC) in major depression. J. Psychiatr. Res. 34:2000;183-186.
42. A receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am. J. Psychiatry. 159:2002;145-147.
43. Ströhle A., Romeo E., Hermann B., Pasini A., Spalletta G., Di Michele F., et al. Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol. Psychiatry. 45:1999;274-277.
44. Sundstrom I., Andersson A., Nyberg S., Ashbrook D., Purdy R.H., Bäckstrom T. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology. 67:1998;126-138.
45. Tan S.Y., Antonipillai I., Murphy B.E.P. Inhibition of testosterone metabolism in the human prostate. J. Clin. Endocrinol. Metab. 39:1974;936-941.
46. Tsutsui K., Ukena K., Takase M., Kohchi C., Lea R.W. Neurosteroid biosynthesis in vertebrate brains. Comp. Biochem. Physiol. 124:1999;121-129.
47. Uzunov D.P., Cooper T.B., Costa E., Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc. Natl Acad. Sci. USA. 93:1996;12599-12604.
48. Uzunova V., Sheline Y., Davis J.M., Rasmusson A., Uzunov D.P., Costa E., et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl Acad. Sci. USA. 95:1998;3239-3244.
49. Wang M.D., Bäckstrom T., Landgren S. The inhibitory effects of allopregnanolone and pregnanolone on the population spike, evoked in the rat hippocampal CA1 stratum pyramidale in vitro, can be blocked selectively by epiallopregnanolone. Acta Physiol. Scand. 169:2000;333-341.
50. Wang M., Seippel L., Purdy R.H., Bäckstrom T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one. J. Clin. Endocrinol. Metab. 81:1996;1076-1082.
51. Wessely S., Chalder T., Hirsch S., Wallace P., Wright D. Psychological symptoms, somatic symptoms, and psychiatric disorder in chronic fatigue and chronic fatigue syndrome: a prospective study in the primary care setting. Am. J. Psychiatry. 153:1996;1050-1059.
52. Wilson J.D., Foster D.W. Williams Textbook of Endocrinology. 1988;WB Saunders, Philadelphia. (Back cover).
53. de Wit H., Rukstalis M. Acute effects of triazolam in women: relationships with progesterone, estradiol and allopregnanolone. Psychopharmacology. 130:1997;69-78.
54. Yu R., Ticku M.K. Chronic neurosteroid treatment produces functional heterologous uncoupling at the gamma-aminobutyric acid type A/benzodiazepine receptor complex in mammalian cortical neurons. Mol. Pharmacol. 47:1995;603-610.
55. Zinder O., Dar D.E. Neuroactive steroids: their mechanism of action and their function in the stress response. Acta Physiol. Scand. 167:1999;181-188.